SCHEMBL4134491

SCHEMBL4134491

COC(=O)C=Cc1cccc(NC(=O)c2ccc(N3CCN(C(=O)OC(C)(C)C)CC3)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.49
MAPT P10636 4/20 0.49
ABCB1 P08183 4/20 0.49
LMNA P02545 2/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CYP2C19 P33261 1/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
TSHR P16473 1/20 0.48
NAMPT P43490 1/20 0.48
PARP14 Q460N5 1/20 0.47
GPR119 Q8TDV5 2/20 0.45
USP2 O75604 1/20 0.45
TP53 P04637 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
PKM P14618 1/20 0.44
ALDH1A1 P00352 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2452211 1.00 SMN1; SMN2 (0.49) SMN1; SMN2MAPTABCB1LMNAMEN1
SCHEMBL11889804 0.88 PKM (0.51) MAPTCYP2C19HTTTSHRPARP14
SCHEMBL11889803 0.88 PKM (0.51) MAPTCYP2C19HTTTSHRPARP14
SCHEMBL11889854 0.83 GPR119 (0.59) SMN1; SMN2MAPTLMNAMEN1KMT2A
SCHEMBL2453979 0.82 SMN1; SMN2 (0.54) SMN1; SMN2MAPTLMNAMEN1KMT2A
SCHEMBL2304722 0.82 MAPT (0.58) SMN1; SMN2MAPTLMNAMEN1KMT2A
SCHEMBL5081454 0.81 NAMPT (0.65) SMN1; SMN2MAPTLMNAMEN1KMT2A
SCHEMBL30182423 0.80 MAPT (0.69) SMN1; SMN2MAPTLMNAMEN1KMT2A
SCHEMBL29803251 0.80 MAPT (0.69) SMN1; SMN2MAPTLMNAMEN1KMT2A
SCHEMBL2452210 0.79 PKM (0.46) SMN1; SMN2MAPTLMNATSHRUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799663-B1 Modulators of HCV replication ANGELETTI P IST RICHERCHE BIO (IT) 2012-08-01 EP claimed
US-20090069344-A1 Modulators of hcv replication ISTITUTO DI RICERCHE BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-03-12 US claimed
EP-1799663-B1 Modulators of HCV replication ANGELETTI P IST RICHERCHE BIO (IT) 2012-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069344-A1 Modulators of hcv replication EIF2AK2, IRF3, IFNAR1 SMN1; SMN2 4644/4885MAPT 4662/4885ABCB1 2029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.